Article

Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo.

Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
Diabetes (Impact Factor: 7.9). 10/2001; 50(9):2139-47.
Source: PubMed

ABSTRACT Nonenzymatic glycation appears to be an important factor in the pathogenesis of diabetic complications. Key early intermediates in this process are fructosamines, such as protein-bound fructoselysines. In this report, we describe the purification and characterization of a mammalian fructosamine-3-kinase (FN3K), which phosphorylates fructoselysine (FL) residues on glycated proteins, to FL-3-phosphate (FL3P). This phosphorylation destabilizes the FL adduct and leads to its spontaneous decomposition, thereby reversing the nonenzymatic glycation process at an early stage. FN3K was purified to homogeneity from human erythrocytes and sequenced by means of electrospray tandem mass spectrometry. The protein thus identified is a 35-kDa monomer that appears to be expressed in all mammalian tissues. It has no significant homology to other known proteins and appears to be encoded by genomic sequences located on human chromosomes 1 and 17. The lability of FL3P, the high affinity of FN3K for FL, and the wide distribution of FN3K suggest that the function of this enzyme is deglycation of nonenzymatically glycated proteins. Because the condensation of glucose and lysine residues is an ubiquitous and unavoidable process in homeothermic organisms, a deglycation system mediated by FN3K may be an important factor in protecting cells from the deleterious effects of nonenzymatic glycation. Our sequence data of FN3K are in excellent agreement with a recent report on this enzyme by Delpierre et al. (Diabetes 49:1627-1634, 2000).

0 Bookmarks
 · 
53 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence demonstrates that advanced glycation end products (AGEs) play a pivotal role in the development and progression of diabetic heart failure, although there are numerous other factors that mediate the disease response. AGEs are generated intra- and extracellularly as a result of chronic hyperglycemia. Then, following the interaction with receptors for advanced glycation end products (RAGEs), a series of events leading to vascular and myocardial damage are elicited and sustained, which include oxidative stress, increased inflammation, and enhanced extracellular matrix accumulation resulting in diastolic and systolic dysfunction. Whereas targeting glycemic control and treating additional risk factors, such as obesity, dyslipidemia, and hypertension, are mandatory to reduce chronic complications and prolong life expectancy in diabetic patients, drug therapy tailored to reducing the deleterious effects of the AGE-RAGE interactions is being actively investigated and showing signs of promise in treating diabetic cardiomyopathy and associated heart failure. This review shall discuss the formation of AGEs in diabetic heart tissue, potential targets of glycation in the myocardium, and underlying mechanisms that lead to diabetic cardiomyopathy and heart failure along with the use of AGE inhibitors and breakers in mitigating myocardial injury.
    Heart Failure Reviews 02/2013; · 4.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The advanced glycoxidation and lipoxidation end products (AGEs and ALEs) contribute to the development of diabetic complications and development of other pathologies. The review discusses the possibilities of counteracting the formation and stimulating degradation of these species by pharmaceuticals and natural compounds. The review discusses inhibitors of ALEs and AGEs formation, crosslink breakers, ALEs/AGEs elimination by enzymes and proteolytic systems, the receptors for advanced glycation end products (RAGE) and blockade of the ligand-RAGE axis.
    Free Radical Research 04/2013; · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In our previous publication we reported on the advantages of using birds as pathology-free model of type-2 diabetes (T2DM). Using this new perspective, we observed that birds are missing the RAGE gene, considered an important factor in the development of diabetic complications. In this paper, we identify two additional Maillard-reaction-related characteristics of birds that may, in part, account for their ability to cope successfully with chronic hyperglycemia. A. Compared to mammals, blood plasma of birds has significantly higher concentrations of taurine and other free amino acids that act as scavengers of reactive carbonyls. B. There are also indications that avian blood-plasma contains lower concentrations of methylglyoxal (MG) due, in part, to its decreased production by avian erythrocytes. Our deductions are based on relatively meager experimental data and are therefore somewhat speculative. One certain outcome of our study, however, is the idea that birds are a productive venue for the study of Maillard reactions and etiology of diabetic complications. We anticipate that results of such studies will support the hypothesis identifying methylglyoxal as a key intermediate in the development of diabetic complications. If methylglyoxal is indeed such a central player, then prevention and control of diabetic complications may become transformed into more a circumscribed and tractable problem whose goals will be to minimize the production of MG and to maximize its elimination by detoxification or by scavenging.
    Rejuvenation Research 03/2014; · 2.92 Impact Factor